Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.

por Kovatcheva, Marta, Klein, Mary E., Tap, William D., Koff, Andrew
Publicado 2017

ATRX is a regulator of therapy induced senescence in human cells

por Kovatcheva, Marta, Liao, Will, Klein, Mary E., Robine, Nicolas, Geiger, Heather, Crago, Aimee M., Dickson, Mark A., Tap, William D., Singer, Samuel, Koff, Andrew
Publicado 2017

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors

por Tula-Sanchez, Ana A, Havas, Aaron P, Alonge, Peter J, Klein, Mary E, Doctor, Samantha R, Pinkston, William, Glinsmann-Gibson, Betty J, Rimsza, Lisa M, Smith, Catharine L
Publicado 2013

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

por Klein, Mary E., Dickson, Mark A., Antonescu, Cristina, Qin, Li-Xuan, Dooley, Scott J., Barlas, Afsar, Manova, Katia, Schwartz, Gary K., Crago, Aimee M., Singer, Samuel, Koff, Andrew, Tap, William D.
Publicado 2018

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

por Kovatcheva, Marta, Liu, David D., Dickson, Mark A., Klein, Mary E., O'Connor, Rachael, Wilder, Fatima O., Socci, Nicholas D., Tap, William D., Schwartz, Gary K., Singer, Samuel, Crago, Aimee M., Koff, Andrew
Publicado 2015